Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats

Am J Physiol. 1992 Nov;263(5 Pt 2):H1331-8. doi: 10.1152/ajpheart.1992.263.5.H1331.

Abstract

We investigated the regulatory effects of the vasoconstrictor thromboxane A2 on the proliferation of vascular smooth muscle cells (VSMC) from Wistar-Kyoto rats using 9,11-epithio-11,12-methano-thromboxane A2 (STA2), a stable analogue of thromboxane A2. STA2 dose dependently increased incorporation of [3H]thymidine into DNA in randomly cycling VSMC and significantly shortened the doubling time. Cell cycle analysis revealed that the increased cell cycle progression was primarily due to a rapid transition from the DNA synthetic (S) to the G2/mitotic (M) phase. Moreover, STA2 enhanced protein synthesis in VSMC during the G2/M phase, whereas the protein synthesis was unaffected in the G0/G1 period. In fact, STA2 prompted the cells in G2/M phase to synthesize actin, a major cytoskeleton protein. Conversely, inhibition of protein synthesis by puromycin retarded the transition from S to G2/M. In addition, depolymerization of the actin molecules by cytochalasin D offset the quick progression to the G2/M phase by STA2. These data indicate that thromboxane A2 stimulates the cell cycle progression in VSMC primarily through a rapid transition from S to G2/M. This enhanced progression is attributable partly to a rapid buildup of the cytoskeleton proteins during the G2/M period.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cell Division / physiology
  • Cells, Cultured
  • Cytoskeletal Proteins / biosynthesis
  • Muscle, Smooth, Vascular / cytology*
  • Muscle, Smooth, Vascular / metabolism
  • Rats
  • Rats, Inbred WKY
  • Thromboxane A2 / analogs & derivatives
  • Thromboxane A2 / pharmacology
  • Thromboxane A2 / physiology*

Substances

  • Cytoskeletal Proteins
  • Thromboxane A2
  • STA 2